Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$6.20 USD
-0.14 (-2.21%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.22 +0.02 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Cullinan Therapeutics, Inc.'s return on equity, or ROE, is -36.56% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that CGEM has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CGEM 6.20 -0.14(-2.21%)
Will CGEM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
180 Bearish Setup appears for CGEM after 2.21% move
CGEM forms Stochastic Buy Signal on September 18
Is CGEM signaling selling opportunity? New 52 Week Closing Low shows up after crashing 5.72%
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
New 52 Week Closing Low appears for CGEM after 0.94% move